YC-1 (Highly Pure)

<strong>YC-1 (Highly Pure)</strong>_x000D_ <strong>Catalog number:</strong> B2014177_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 2.5 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 304.34 g/mol_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> RT_x000D_ <strong>Keywords:</strong> 3-(5′-Hydroxymethyl-2′-furyl)-1-benzyl indazole_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Yu KH, Hung HY. Synthetic strategy and structure-activity relationship (SAR) studies of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1, Lificiguat): a review RSC Adv. 2021 Dec 20;12(1):251-264._x000D_ 2: Ouyang C, Zhang J, Lei X, Xie Z, Liu X, Li Y, Huang S, Wang Z, Tang G. Advances in antitumor research of HIF-1 inhibitor YC-1 and its derivatives Bioorg Chem. 2023 Apr;133:106400._x000D_ 3: Chun YS, Yeo EJ, Park JW. Versatile pharmacological actions of YC-1: anti-platelet to anticancer Cancer Lett. 2004 Apr 15;207(1):1-7._x000D_ 4: Hu H, Miao XK, Li JY, Zhang XW, Xu JJ, Zhang JY, Zhou TX, Hu MN, Yang WL, Mou LY. YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1 and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells Eur J Pharmacol. 2020 May 5;874:172961._x000D_ 5: Harada T, Hirose K, Wada Y, Sato M, Ichise K, Aoki M, Kato T, Takeda K, Takai Y. YC-1 sensitizes the antitumor effects of boron neutron capture therapy in hypoxic tumor cells J Radiat Res. 2020 Jul 6;61(4):524-534._x000D_ 6: Wu JY, Shih YL, Lin SP, Hsieh TY, Lin YW. YC-1 Antagonizes Wnt/_-Catenin Signaling Through the EBP1 p42 Isoform in Hepatocellular Carcinoma Cancers (Basel). 2019 May 13;11(5):661._x000D_ 7: Pal B, Kitagawa T. Binding of YC-1/BAY 41-2272 to soluble guanylate cyclase: A new perspective to the mechanism of activation Biochem Biophys Res Commun. 2010 Jul 2;397(3):375-9._x000D_ 8: Tsui L, Chang SF, Huang HP, Fong TH, Wang IJ. YC-1 induces lipid droplet formation in RAW 264.7 macrophages J Biomed Sci. 2016 Jan 15;23:2._x000D_ 9: Jin Q, Zheng J, Chen M, Jiang N, Xu X, Huang F. HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib Oxid Med Cell Longev. 2021 Mar 3;2021:6633867._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/15320784">10: Tulis DA. Salutary properties of YC-1 in the cardiovascular and hematological systems Curr Med Chem Cardiovasc Hematol Agents. 2004 Oct;2(4):343-59. </a>_x000D_ _x000D_ <strong>Products Related to YC-1 (Highly Pure) can be found at</strong> <a href="https://moleculardepot.com/product-category/Chemicals/"> Chemicals</a>